Clinical and pathological features of Burkitt lymphoma showing expression of BCL2 - an analysis including gene expression in formalin-fixed paraffin-embedded tissue

Autor: Monika Szczepanowski, Inga Nagel, Birgit Burkhardt, Reiner Siebert, Wolfram Klapper, Sietse M. Aukema, Christian W. Kohler, Rainer Spang, Neus Masqué-Soler, Julia Richter
Rok vydání: 2015
Předmět:
Male
ddc:004
Pathology
medicine.medical_specialty
Tissue Fixation
Adolescent
Formalin fixed paraffin embedded
Genes
myc
610 Medizin
Biology
Translocation
Genetic
Diagnosis
Differential
Young Adult
immune system diseases
Formaldehyde
hemic and lymphatic diseases
Gene expression
medicine
Humans
570 Biowissenschaften
Biologie
Child
neoplasms
Pathological
NanoString
nCounter
classifier
Burkitt
diffuse large B-cell lymphoma
MYC
ddc:610
Paraffin Embedding
Hematology
004 Informatik
medicine.disease
Burkitt Lymphoma
Genes
bcl-2
Neoplasm Proteins
Lymphoma
Gene Expression Regulation
Neoplastic
Gene expression profiling
Treatment Outcome
Proto-Oncogene Proteins c-bcl-2
Child
Preschool
biology.protein
Female
Lymphoma
Large B-Cell
Diffuse
ddc:570
biological phenomena
cell phenomena
and immunity
Antibody
Differential diagnosis
Diffuse large B-cell lymphoma
Zdroj: British Journal of Haematology. 171:501-508
ISSN: 0007-1048
Popis: The differential diagnosis between Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) can be challenging. BL has been reported to express less BCL2 than DLBCL, but this issue has not been analysed systematically. BL expressing BCL2 can be considered to be MYC/BCL2 co-expressors, a feature that is associated with poorer outcome in DLBCL but that has not been correlated with outcome in BL so far. We analysed the expression of BCL2 in 150 cases of conventionally diagnosed BL using two different BCL2 antibodies. BCL2 expression was detected in 23% of the cases, though the expression varied in intensity and number of positive cells. We did not detect any relevant differences in clinical presentation and outcome between BCL2-positive and BCL2-negative BL in a subgroup of 43 cases for which detailed clinical data were available. An independent cohort of 17 BL with expression of BCL2 were analysed molecularly, with 13 of 17 cases classified as molecularly defined BL (Burkitt Lymphoma) using gene expression profiling on formalin-fixed paraffin-embedded tissues. The four lymphomas diagnosed molecularly as intermediates did not differ in clinical presentation and outcome from molecularly defined BL.
Databáze: OpenAIRE
Externí odkaz: